# Novavax (NVAX) — Earnings

NVAX · NASDAQ · Stock

Canonical page: https://www.lighthorse.io/tickers/nvax/earnings

## Most recent quarter

| Metric | Value |
| --- | --- |
| Fiscal period | Q2 2026 |
| Period end | Jun 30, 2026 |
| EPS actual | −$0.32 |
| EPS estimate | −$0.38 |
| EPS surprise | +15.75% |
| Revenue surprise | +7.97% |
| Revenue | $56.7M |
| Revenue estimate | $52.5M |
| Reported | Aug 6, 2026 |
| SEC filing | [View filing](https://www.sec.gov:443/Archives/edgar/data/1000694/000100069426000018/nvax-20260630.htm) |
| Earnings call | [Transcript](http://o.thsi.cn/dc-d-stock-america.teleconference/87bdc97c-de87-0267-8250-8f6b6ce36bca.html) |

Novavax reported Q2 2026 results on August 6, 2026. It posted a loss of $0.32 per share, narrower than the $0.38 loss analysts expected, a 15.75% beat. Revenue was $56.7 million against a $52.5 million estimate, about 8% higher. A year earlier, in Q2 2025, Novavax earned $0.62 per share on revenue of $239.2 million, so revenue fell about 76% year over year.

Results swing widely. Revenue ranged from $56.7 million in Q2 2026, the lowest here, to $734.6 million in Q3 2022. Novavax lost money in 14 of the last 20 quarters. Annual results improved each year: a loss of $8.40 per share in 2022, $5.53 in 2023 and $1.33 in 2024, then a profit of $2.41 in 2025. Q1 2025 was the strongest quarter in the table, at $2.93 per share on $666.7 million in revenue. The first half of 2026 shows a combined $0.38 loss, against a $3.55 profit a year earlier. Novavax beat EPS estimates in 11 of the 20 quarters.

Past Q3 reports came between November 5 and November 12, which points to early or mid-November 2026. The next report will show whether revenue recovers from the Q2 level.

## Earnings history

| Fiscal period | Report date | EPS estimate | EPS actual | Surprise | Revenue estimate | Revenue actual |
| --- | --- | --- | --- | --- | --- | --- |
| Q2 2026 | Aug 6, 2026 | −$0.38 | −$0.32 | 15.75% | $52.5M | $56.7M |
| Q1 2026 | May 6, 2026 | −$0.24 | −$0.06 | 75.19% | $79.8M | $139.5M |
| Q4 2025 | Feb 26, 2026 | −$0.48 | $0.11 | 122.69% | $89.8M | $147.1M |
| Q3 2025 | Nov 6, 2025 | −$1.20 | −$1.25 | -4.49% | $42.1M | $70.4M |
| Q2 2025 | Aug 6, 2025 | $0.01 | $0.62 | 7280.95% | $152.6M | $239.2M |
| Q1 2025 | May 8, 2025 | −$0.42 | $2.93 | 792.18% | $343.9M | $666.7M |
| Q4 2024 | Feb 27, 2025 | −$0.51 | −$0.51 | 0.78% | $84.4M | $88.3M |
| Q3 2024 | Nov 12, 2024 | −$0.79 | −$0.76 | 3.93% | $73.8M | $84.5M |
| Q2 2024 | Aug 8, 2024 | $1.67 | $0.99 | -40.72% | $458.6M | $415.5M |
| Q1 2024 | May 10, 2024 | −$1.06 | −$1.05 | 1.32% | $101.2M | $93.9M |
| Q4 2023 | Feb 28, 2024 | −$0.45 | −$1.44 | -221.43% | $322.1M | $291.3M |
| Q3 2023 | Nov 9, 2023 | −$2.22 | −$1.26 | 43.12% | $115.4M | $187.0M |
| Q2 2023 | Aug 8, 2023 | −$1.33 | $0.58 | 143.55% | $264.2M | $424.4M |
| Q1 2023 | May 9, 2023 | −$3.46 | −$3.41 | 1.50% | $87.6M | $81.0M |
| Q4 2022 | Feb 28, 2023 | −$1.01 | −$2.28 | -124.85% | $383.1M | $357.4M |
| Q3 2022 | Nov 8, 2022 | $1.57 | −$2.15 | -237.09% | $586.2M | $734.6M |
| Q2 2022 | Aug 9, 2022 | $3.64 | −$6.53 | -279.23% | $863.7M | $185.9M |
| Q1 2022 | May 10, 2022 | $2.69 | $2.56 | -4.77% | $845.2M | $704.0M |
| Q4 2021 | Mar 1, 2022 | −$1.80 | −$11.18 | -520.42% | $331.8M | $222.2M |
| Q3 2021 | Nov 5, 2021 | −$3.91 | −$4.31 | -10.31% | $334.5M | $178.8M |

## Frequently Asked Questions

### When did Novavax (NVAX) last report earnings?

Novavax last reported on Aug 6, 2026, covering fiscal Q2 2026.

### Did NVAX beat earnings estimates?

Yes. Novavax reported EPS of −$0.32 for Q2 2026 against a −$0.38 estimate — a 15.75% beat.

### How much revenue did NVAX report last quarter?

Novavax reported $56.7M in revenue for Q2 2026, against a consensus estimate of $52.5M.

## Similar Stocks

- [MRNA](https://www.lighthorse.io/tickers/mrna) — Moderna, Inc. - Common Stock
- [PFE](https://www.lighthorse.io/tickers/pfe) — Pfizer, Inc. Common Stock
- [JNJ](https://www.lighthorse.io/tickers/jnj) — Johnson & Johnson Common Stock
- [AZN](https://www.lighthorse.io/tickers/azn) — AstraZeneca PLC Ordinary Shares
- [OCGN](https://www.lighthorse.io/tickers/ocgn) — Ocugen, Inc. - Common Stock

---

Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.

This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.

Data provided by [AInvest](https://www.ainvest.com).